[
    [
        {
            "time": "",
            "original_text": "康泰生物：灭活新冠疫苗尚未有境外收入",
            "features": {
                "keywords": [
                    "康泰生物",
                    "灭活新冠疫苗",
                    "境外收入"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：灭活新冠疫苗尚未有境外收入",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：公司已建成13价肺炎球菌结合疫苗车间且13价肺炎球菌多糖结合疫苗已获得药品注册证书，将积极安排生产、供应",
            "features": {
                "keywords": [
                    "康泰生物",
                    "13价肺炎球菌结合疫苗",
                    "药品注册证书",
                    "生产供应"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物：公司已建成13价肺炎球菌结合疫苗车间且13价肺炎球菌多糖结合疫苗已获得药品注册证书，将积极安排生产、供应",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：冻干人用狂犬病疫苗（人二倍体细胞）按照新的《药品注册管理办法（2020年）》在申请药品注册批件中",
            "features": {
                "keywords": [
                    "康泰生物",
                    "冻干人用狂犬病疫苗",
                    "药品注册管理办法",
                    "注册批件"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：冻干人用狂犬病疫苗（人二倍体细胞）按照新的《药品注册管理办法（2020年）》在申请药品注册批件中",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：公司当前在进一步加强产品在海外的注册工作，积极开拓国际市场",
            "features": {
                "keywords": [
                    "康泰生物",
                    "海外注册",
                    "国际市场"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物：公司当前在进一步加强产品在海外的注册工作，积极开拓国际市场",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：股东YUAN LIPING女士已将700万股股份转让给其持有100%份额的私募基金产品，该部分股份仍由其间接控制，不涉及二级市场减持\n减持股份",
            "features": {
                "keywords": [
                    "康泰生物",
                    "股东",
                    "股份转让",
                    "私募基金",
                    "二级市场减持"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：股东YUAN LIPING女士已将700万股股份转让给其持有100%份额的私募基金产品，该部分股份仍由其间接控制，不涉及二级市场减持\n减持股份",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周观点：医药生物板块回暖 逐步进入合理配置区间",
            "features": {
                "keywords": [
                    "医药生物",
                    "板块回暖",
                    "合理配置区间"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周观点：医药生物板块回暖 逐步进入合理配置区间",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]